Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)
- PMID: 23872191
- DOI: 10.1016/j.ygyno.2013.07.084
Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)
Abstract
Objective: Despite the very good prognosis of endometrial cancer, a number of patients with localized disease relapse following surgery. Therefore, various adjuvant therapeutic approaches have been studied. The objective of this review is to evaluate the efficacy and safety of neoadjuvant and adjuvant therapies in patients with resectable endometrial cancer and to develop evidence-based recommendations.
Methods: A review of the scientific literature published between January 1990 and June 2012 was performed. The search was limited to published phase III clinical trials and meta-analyses evaluating the efficacy of neoadjuvant or adjuvant therapies in patients with endometrial carcinoma or carcinosarcoma. A total of 23 studies and five meta-analyses were identified.
Results: The selected literature showed that in patients with a low risk of recurrence, post-surgical observation is safe and recommended in most cases. There are several therapeutic modalities available for treatment of endometrial cancers with higher risk of recurrence, including vaginal brachytherapy, external beam radiotherapy, chemotherapy, or a combination of these.
Conclusions: Considering the evidence available to date, the CEPO recommends the following: (1)post-surgical observation for most patients with a low recurrence risk; (2)adjuvant vaginal brachytherapy for patients with an intermediate recurrence risk; (3)adjuvant pelvic radiotherapy with or without vaginal brachytherapy for patients with a high recurrence risk; addition of adjuvant chemotherapy may be considered as an option for selected patients (excellent functional status, no significant co-morbidities, poor prognostic factors); (4)adjuvant chemotherapy and pelvic radiotherapy with or without brachytherapy and para-aortic irradiation for patients with advanced disease;
Keywords: Adjuvant; Cancer; Chemotherapy; Endometrium; Radiotherapy.
© 2013.
Similar articles
-
[Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)].Cancer Radiother. 2001 Apr;5(2):163-92. Cancer Radiother. 2001. PMID: 11355582 French.
-
Adjuvant treatment of advanced-stage endometrial cancer.Clin Obstet Gynecol. 2011 Jun;54(2):256-65. doi: 10.1097/GRF.0b013e318218c659. Clin Obstet Gynecol. 2011. PMID: 21508695 Review.
-
Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73. doi: 10.1016/j.ijrobp.2003.10.019. Int J Radiat Oncol Biol Phys. 2004. PMID: 15093913 Clinical Trial.
-
Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy?Strahlenther Onkol. 2007 Nov;183(11):600-4. doi: 10.1007/s00066-007-1801-3. Strahlenther Onkol. 2007. PMID: 17960334 Review.
-
[Synchronous primary cancers of the endometrium and ovary: review of 43 cases].Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):690-4. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173912 Chinese.
Cited by
-
Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis.J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.17.00146. J Glob Oncol. 2018. PMID: 30241227 Free PMC article. Clinical Trial.
-
Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group.J Gynecol Oncol. 2019 Jul;30(4):e53. doi: 10.3802/jgo.2019.30.e53. Epub 2019 Feb 7. J Gynecol Oncol. 2019. PMID: 31074238 Free PMC article.
-
Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy.Radiat Oncol. 2014 Jun 18;9:141. doi: 10.1186/1748-717X-9-141. Radiat Oncol. 2014. PMID: 24941899 Free PMC article.
-
ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro.Front Oncol. 2020 Oct 20;10:577141. doi: 10.3389/fonc.2020.577141. eCollection 2020. Front Oncol. 2020. PMID: 33194693 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials